Fox Run Management L.L.C. purchased a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,900 shares of the biotechnology company’s stock, valued at approximately $259,000.
Several other large investors have also modified their holdings of the company. BlackRock Inc. grew its position in shares of Ligand Pharmaceuticals by 2.6% in the second quarter. BlackRock Inc. now owns 2,683,880 shares of the biotechnology company’s stock valued at $325,822,000 after purchasing an additional 68,887 shares during the last quarter. William Blair Investment Management LLC grew its position in shares of Ligand Pharmaceuticals by 2.6% in the second quarter. William Blair Investment Management LLC now owns 1,773,434 shares of the biotechnology company’s stock valued at $215,295,000 after purchasing an additional 45,256 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Ligand Pharmaceuticals by 3.2% in the second quarter. Vanguard Group Inc. now owns 1,741,818 shares of the biotechnology company’s stock valued at $211,457,000 after purchasing an additional 54,200 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Ligand Pharmaceuticals in the second quarter valued at about $72,293,000. Finally, Eagle Asset Management Inc. grew its position in shares of Ligand Pharmaceuticals by 7.7% in the second quarter. Eagle Asset Management Inc. now owns 490,841 shares of the biotechnology company’s stock valued at $59,588,000 after purchasing an additional 35,289 shares during the last quarter.
In other Ligand Pharmaceuticals news, CEO John L. Higgins sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $130.00, for a total transaction of $650,000.00. Following the sale, the chief executive officer now directly owns 144,171 shares of the company’s stock, valued at $18,742,230. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason Aryeh sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $127.99, for a total value of $255,980.00. Following the sale, the director now directly owns 59,625 shares in the company, valued at $7,631,403.75. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by insiders.
Shares of Ligand Pharmaceuticals Incorporated (LGND) opened at $142.80 on Tuesday. Ligand Pharmaceuticals Incorporated has a 1 year low of $95.08 and a 1 year high of $149.31. The firm has a market capitalization of $2,952.66, a PE ratio of 105.19, a P/E/G ratio of 2.16 and a beta of 0.94. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.32. The business had revenue of $33.38 million for the quarter, compared to the consensus estimate of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm’s revenue for the quarter was up 54.4% compared to the same quarter last year. During the same period last year, the business earned $0.62 earnings per share. analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.truebluetribune.com/2017/11/14/fox-run-management-l-l-c-takes-259000-position-in-ligand-pharmaceuticals-incorporated-lgnd.html.
Several equities research analysts have recently issued reports on LGND shares. Zacks Investment Research downgraded Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $157.00 price target on shares of Ligand Pharmaceuticals in a research report on Thursday, October 5th. Roth Capital reaffirmed a “buy” rating and issued a $158.00 price target (up from $135.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, October 11th. ValuEngine raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, TheStreet raised Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $144.20.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.